

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI)

Last Update: Mar 17, 2025

A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated Acute Kidney Injury (SA-AKI)

ClinicalTrials.gov Identifier:

[NCT05996835](#)

Novartis Reference Number:CTIN816B12202

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI). This is a multicenter, randomized, double-blind, placebo-controlled, four-arm, parallel-group, dose-finding phase 2b study. The study will enroll hospitalized adult participants with a diagnosis of sepsis and acute kidney injury (AKI). The study consists of a screening period (24-48 hours), a treatment period (Day 1), and post-treatment period (Day 2 to 90). Screening will take place during hospitalization in ICU (or intermediate care unit/HDU) where potential participants will undergo screening to assess the presence of sepsis and AKI. At Treatment Day 1, participants who meet eligibility criteria at screening and baseline will be randomized in a 3:1:1:3 ratio to receive a one-time treatment of TIN816 or placebo by intravenous infusion in a participant and investigator-blinded fashion. Treatment Day 1 is followed by a 90-day post-treatment period for safety and efficacy assessments. An interim analysis (IA) is planned when approximately 120 participants complete Day 30 visit. A final analysis will be performed after all participants have completed Day 90.

Condition

Acute Kidney Injury Due to Sepsis

Phase

Phase2

Overall Status

Recruiting

Number of Participants

320

Start Date

Jan 18, 2024

Completion Date

Feb 20, 2026

Gender

All

Age(s)

18 Years - 85 Years (Adult, Older Adult)

Interventions

Other

Placebo

0.9% sterile saline solution

Biological

TIN816 70 mg lyophilisate powder

Immunotherapy Recombinant human CD39 enzyme

Eligibility Criteria

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study.
2. ≥ 18 to ≤ 85 years of age
3. Admitted to ICU or intermediate care unit/ high dependency care unit (HDU)
4. Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on:

* Suspected or confirmed infection AND

* Acute increase of SOFA score of 2 or more (excluding renal component). The baseline SOFA score should be assumed to be zero unless the participant is known to have pre-existing (acute or chronic) organ dysfunction before the onset of infection

5. Diagnosis of AKI Stage 1 or greater per the following criterion at randomization:

An absolute increase in serum or plasma creatinine by ≥ 0.3 mg/dL (≥ 26.5 $\mu\text{mol/L}$) within 48 hours or presumed to have occurred in the previous 48 hours as compared to the reference serum creatinine.

* For participants with hospital-acquired AKI, a stable serum creatinine obtained in the hospital prior to AKI diagnosis should be used as the reference serum creatinine.

* For participants presenting from community, the reference serum creatinine should be estimated using the following order of preference:

1. The most recent value within 3 months of the hospital admission. If not available:
2. The most recent value between 3 and 12 months prior to hospital admission. If not available:
3. At hospital admission

Exclusion criteria

1. Not expected to survive for 24 hours
2. Not expected to survive for 30 days due to medical conditions other than SA-AKI

3. History of CKD with a documented estimated GFR ≤ 45 mL/min prior to admission to hospital
4. eGFR ≤ 45 mL/min at admission without any other reference serum eGFR within last 12-months
5. Receiving RRT or a decision has been made to initiate RRT within 24 hours after randomization
6. Weight is less than 40 kg or more than 125 kg.
7. Limitations to the use of mechanical ventilation, RRT or vasopressors/inotropes (N.B. limitations on Cardiopulmonary resuscitation (CPR) e.g., do-not-resuscitate orders are not an exclusion criterion unless associated with likely poor outcome in next 24 hours)
8. Sepsis diagnosis according to sepsis inclusion criteria for a period longer than 72 hours prior to ICU admission
9. AKI diagnosis according to AKI inclusion criteria over 48 hours after admission to ICU
10. Inability to administer study drug within 24 hours of diagnosis of AKI according to AKI inclusion criteria
11. Presence of AKI, in the Investigator's opinion, as suggested by clinical manifestation, e.g., prolonged oliguria or severe renal dysfunction on admission without a history of CKD, for a period longer than 24 hours prior to study drug administration
12. Evidence of recovery from AKI based on the investigator's clinical judgement prior to randomization
13. AKI is most likely attributable to other causes than sepsis, such as nephrotoxic drugs (Non-steroidal anti-inflammatory drugs (NSAIDs), contrast, aminoglycosides, etc.) or renal perfusion-related (acute abdominal aortic aneurysm, dissection, renal artery stenosis), urinary obstruction
14. Documented (biopsy proven) or suspected history of acute or sub-acute kidney diseases such as rapidly progressive glomerular nephritis (RPGN) and acute interstitial nephritis (AIN)
15. Patients who are post-nephrectomy
16. Patients with permanent incapacitation
17. Patients who are thrombocytopenic at screening (platelet count $\leq 50,000$ per microliter) who have active/uncontrolled bleeding or who present current or past conditions indicating high risk for bleeding in the opinion of the investigator (e.g. coagulopathies, previous history of major non-traumatic bleeding etc.)
18. Immunosuppressed patients

* History of immunodeficiency diseases

* Receiving immunosuppressant treatment or on chronic high doses (high-dose therapy exceeding 2 weeks of treatment) of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with corticosteroids (as per the Surviving Sepsis Guidelines) can be included. See Appendix Section 10.6 Immunosuppressant drugs, (Table 10 5 Immunosuppressant drug exclusions)

19. Patients with known or presumed latent or active TB based on clinical history or imaging e.g. patients on TB preventive therapy or close/household contacts of pulmonary TB patients
20. Known active hepatitis B or C infection, or positive Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) serology or patients with advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C)
21. Acute pancreatitis with no established source of infection
22. Active hematological malignancy (previous hematological malignancies that are not actively treated are allowable)
23. Burns requiring ICU treatment
24. Sepsis attributed to confirmed COVID-19
25. Use of other investigational drugs within 5 half-lives of enrollment, within 30 days (e.g., small molecules) or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations
26. History of hypersensitivity to the study treatment or its excipients or to drugs of similar chemical classes
27. Any medical conditions that could significantly increase risk of participants' safety by participating in this study according to investigator's judgement

28. Women with a positive pregnancy test, pregnancy or breast feeding

29. Women of childbearing potential, unless they are using highly effective methods of contraception for the entire duration of the trial.

Australia

Novartis Investigative Site

Recruiting

Heidelberg,Victoria,3084,Australia

Novartis Investigative Site

Recruiting

Herston,Queensland,4029,Australia

Austria

Novartis Investigative Site

Recruiting

Innsbruck,Tyrol,6020,Austria

Belgium

Novartis Investigative Site

Recruiting

Gent,9000,Belgium

Novartis Investigative Site

Recruiting

Ottignies,1340,Belgium

Novartis Investigative Site

Recruiting

Bruxelles,1200,Belgium

Novartis Investigative Site

Recruiting

Genk,3600,Belgium

Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,01327 001,Brazil

Novartis Investigative Site

Recruiting

Santo Andre,SP,09090-790,Brazil

Novartis Investigative Site

Recruiting

Salvador,40301-155,Brazil

Novartis Investigative Site

Recruiting

Brasilia,DF,70390-140,Brazil

Novartis Investigative Site

Recruiting

Curitiba,Parana,80010 030,Brazil

Canada

Novartis Investigative Site

Recruiting

Vancouver,British Columbia,V6z 1y6,Canada

Novartis Investigative Site

Recruiting

Kingston,Ontario,K7l 2v7,Canada

Novartis Investigative Site

Recruiting

Montreal,Quebec,H2w 1t8,Canada

Novartis Investigative Site

Recruiting

Montreal,Quebec,H4j 1c5,Canada

Novartis Investigative Site

Recruiting

Sainte Foy,Quebec,G1v 4g5,Canada

China

Novartis Investigative Site

Recruiting

Zhengzhou,Henan,450003,China

Novartis Investigative Site

Recruiting

Shijiazhuang,Hebei,050011,China

Novartis Investigative Site

Recruiting

Hangzhou,Zhejiang,310014,China

Novartis Investigative Site

Recruiting

Beijing,100730,China

Novartis Investigative Site

Recruiting

Guang Zhou,510260,China

Novartis Investigative Site

Recruiting

Wuhan,430022,China

France

Novartis Investigative Site

Recruiting

Toulouse 4,31054,France

Novartis Investigative Site

Recruiting

Argenteuil,95107,France

Novartis Investigative Site

Recruiting

Garches,92380,France

Novartis Investigative Site

Recruiting

Le Kremlin Bicetre,94275,France

Novartis Investigative Site

Recruiting

Nantes Cedex 1,44093,France

Novartis Investigative Site

Recruiting

Pessac,33604,France

Novartis Investigative Site

Recruiting

Paris cedex 10,75010,France

Novartis Investigative Site

Recruiting

Strasbourg Cedex,67091,France

Novartis Investigative Site

Recruiting

Limoges,Haute Vienne,87000,France

Germany

Novartis Investigative Site

Recruiting

Jena,07740,Germany

Novartis Investigative Site

Recruiting

Kiel,24105,Germany

Novartis Investigative Site

Recruiting

Essen,45147,Germany

Novartis Investigative Site

Recruiting

Muenchen,81377,Germany

Novartis Investigative Site

Recruiting

Muenster,48149,Germany

Novartis Investigative Site

Recruiting

Stuttgart,70376,Germany

Novartis Investigative Site

Recruiting

Frankfurt am Main,Hessen,60590,Germany

Hungary

Novartis Investigative Site

Recruiting

Szekesfehervar,H-8000,Hungary

Novartis Investigative Site

Recruiting

Budapest,H-1097,Hungary

Novartis Investigative Site

Recruiting

Gyor,H-9024,Hungary

Novartis Investigative Site

Recruiting

Debrecen,4032,Hungary

India

Novartis Investigative Site

Recruiting

Ahmedabad,Gujarat,380 060,India

Novartis Investigative Site

Recruiting

Pune,Maharashtra,411 011,India

Novartis Investigative Site

Recruiting

Delhi,110001,India

Novartis Investigative Site

Recruiting

Belgavi,590010,India

Novartis Investigative Site

Recruiting

Hyderabad,500034,India

Italy

Novartis Investigative Site

Recruiting

Milano,MI,20162,Italy

Novartis Investigative Site

Recruiting

Rozzano,MI,20089,Italy

Novartis Investigative Site

Recruiting

Padova,PD,35128,Italy

Novartis Investigative Site

Recruiting

Perugia,PG,06129,Italy

Novartis Investigative Site

Recruiting

Roma,RM,00168,Italy

Novartis Investigative Site

Recruiting

Bologna,BO,40138,Italy

Novartis Investigative Site

Recruiting

Napoli,80131,Italy

Novartis Investigative Site

Recruiting

Milano,MI,20100,Italy

Japan

Novartis Investigative Site

Recruiting

Izumisano-city,Osaka,598-8577,Japan

Novartis Investigative Site

Recruiting

Izumo,Shimane,693-0068,Japan

Novartis Investigative Site

Recruiting

Hachioji-city,Tokyo,193-0944,Japan

Novartis Investigative Site

Recruiting

Asahikawa,Hokkaido,078 8510,Japan

Novartis Investigative Site

Recruiting

Itabashi-ku,Tokyo,173-8610,Japan

Novartis Investigative Site

Recruiting

Kumamoto,862-8505,Japan

Novartis Investigative Site

Recruiting

Kamogawa,Chiba,296-8602,Japan

Novartis Investigative Site

Recruiting

Osaka,534-0021,Japan

Novartis Investigative Site

Recruiting

Fukuoka city,Fukuoka,812-8582,Japan

Novartis Investigative Site

Recruiting

Ureshino,Saga,843-0393,Japan

South Africa

Novartis Investigative Site

Recruiting

Pretoria,0002,South Africa

Spain

Novartis Investigative Site

Recruiting

Madrid,28041,Spain

Novartis Investigative Site

Recruiting

Cordoba,Andalucia,14004,Spain

Novartis Investigative Site

Recruiting

Valencia,46026,Spain

Novartis Investigative Site

Recruiting

Sabadell,Barcelona,08208,Spain

Novartis Investigative Site

Recruiting

Jerez,Cadiz,11407,Spain

Novartis Investigative Site

Recruiting

Hospitalet de Llobregat,Barcelona,08907,Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08035,Spain

Novartis Investigative Site

Recruiting

Terrassa,Catalunya,08221,Spain

Novartis Investigative Site

Recruiting

Santiago De Compostela,Galicia,15706,Spain

Novartis Investigative Site

Recruiting

Barcelona,08041,Spain

Thailand

Novartis Investigative Site

Recruiting

Bangkok,10330,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10400,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10700,Thailand

Novartis Investigative Site

Recruiting

Chiang Mai,50200,Thailand

Turkey

Novartis Investigative Site

Recruiting

Ankara,06230,Turkey

Novartis Investigative Site

Recruiting

Istanbul,34093,Turkey

United Kingdom

Novartis Investigative Site

Recruiting

Guildford,Surrey,Gu2 7xx,United Kingdom

Novartis Investigative Site

Recruiting

Birmingham,B15 2th,United Kingdom

Novartis Investigative Site

Recruiting

Bristol,Bs2 8hw,United Kingdom

Novartis Investigative Site

Recruiting

London,Se1 7eh,United Kingdom

United States

Temple University

Recruiting

Philadelphia,Pennsylvania,19140,United States

Julia Aruta

Phone: [215-707-2230](tel:215-707-2230)

Email: julia.aruta@temple.edu

Avrum Gillespie

Ohio State University Medical Center

Recruiting

Columbus,Ohio,43210,United States

Connor Lang

Email: connor.lang@osumc.edu

Matthew Exline

Baystate Medical Center

Recruiting

Springfield,Massachusetts,01199,United States

Mark Tidswell

Sarah Romain

Phone: [413-784-5439](tel:413-784-5439)

Email: sarah.romain@baystatehealth.org

Mayo Clinic Rochester

Recruiting

Rochester, Minnesota, 55905, United States

Leah Knoke

Email: knoke.leah@mayo.edu

Kianoush Kashani

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, 02114, United States

Kathryn Hibbert

Charlotte Crutchlow

Phone: [617-724-4000](tel:617-724-4000)

Email: ccrutchlow@mgh.harvard.edu

UC San Francisco Medical Center

Recruiting

San Francisco, California, 94143-0116, United States

Aqsa Khan

Phone: [415-476-2091](tel:415-476-2091)

Email: aqsa.khan@ucsf.edu

Matthieu Legrand

Stanford Healthcare

Recruiting

Stanford, California, 94305 5152, United States

Ronald Pearl

Angelica Pritchard

Email: apritcha@stanford.edu

Baylor Scott and White

Recruiting

Dallas, Texas, 75246, United States

Ankit Mehta

Symone Dunkley

Email: Symone.Dunkley@BSWHealth.org

Montefiore Medical Center

Recruiting

Bronx, New York, 10467, United States

Ari Moskowitz

Ofelia Garcia

Phone: [718-920-2776](tel:718-920-2776)

Email: ofelia.garcia@einsteinmed.edu

Inova Fairfax Hospital

Recruiting

Falls Church, Virginia, 22042, United States

Jun-Ru Dizon

Phone: [703-698-3580](tel:703-698-3580)

Email: Jun-Ru.Dizon@inova.org

Markos Kashiouris

Emory Johns Creek Hospital

Recruiting

Johns Creek, Georgia, 30097, United States

Bethel Henderson

Email: bethel.henderson@emoryhealthcare.org

Venu Velagapudi

Good Samaritan Hospital

Recruiting

Corvallis,Oregon,97330,United States

Brian Delmonaco

Stephanie Mock

Phone: [541-768-5202](tel:541-768-5202)

Email: stmock@samhealth.org

Henry Ford Hospital

Recruiting

Detroit,Michigan,48202 2689,United States

Karen Campana

Phone: [313-876-1850](tel:313-876-1850)

Email: Kcampan1@hfhs.org

Ryann Sohaney

Univ Of Iowa Hospitals And Clinics

Recruiting

Iowa City,Iowa,52242,United States

Benjamin Griffin

Mc Lean Sunderland

Phone: [319-356-1826](tel:319-356-1826)

Email: mclean-sunderland@uiowa.edu

Providence Med Resch Center and Chindren Hosp

Recruiting

Spokane,Washington,99204,United States

Jodie Mactagone

Email: jodie.mactagone@providence.org

Radica Alicic

Wake Forest Univ School of Medicine

Recruiting

Winston-Salem, North Carolina, 27157-1071, United States

Ashish Khanna

Lynnette Harris

Phone: [513-658-5866](tel:513-658-5866)

Email: lharris@wakehealth.edu

Northwestern Memorial Hospital

Recruiting

Evanston, Illinois, 60611, United States

Francisco Martinez

Email: francisco.martinez@northwestern.edu

Richard Wunderink

Utah Intermountain Medical Center

Recruiting

Murray, Utah, 84107, United States

Ithan Peltan

Johnny Trang

Phone: [801-507-9333](tel:801-507-9333)

Email: johnny.trang@imail.org

Montefiore Medical Center

Recruiting

Bronx, New York, 10461, United States

Luke Andrea

Ofelia Garcia

Phone: [718-904-2321](tel:718-904-2321)

Email: ofelia.garcia@einsteinmed.edu

Lahey Hospital and Medical Center

Recruiting

Burlington,Massachusetts,01805,United States

Phone: 781-744-3874

Christopher Hansen

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: +41613241111

Email:

Novartis Pharmaceuticals

Phone: 1-888-669-6682

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct05996835>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05996835>
2. [#trial-eligibility](#)
3. <tel:215-707-2230>
4. <mailto:julia.aruta@temple.edu>
5. <mailto:connor.lang@osumc.edu>
6. <tel:413-784-5439>
7. <mailto:sarah.romain@baystatehealth.org>
8. <mailto:knoke.leah@mayo.edu>
9. <tel:617-724-4000>
10. <mailto:ccrutchlow@mgh.harvard.edu>
11. <tel:415-476-2091>
12. <mailto:aqsa.khan@ucsf.edu>
13. <mailto:apritcha@stanford.edu>
14. <mailto:Symone.Dunkley@BSWHealth.org>
15. <tel:718-920-2776>
16. <mailto:ofelia.garcia@einsteinmed.edu>
17. <tel:703-698-3580>
18. <mailto:Jun-Ru.Dizon@inova.org>
19. <mailto:bethel.henderson@emoryhealthcare.org>
20. <tel:541-768-5202>
21. <mailto:stmock@samhealth.org>
22. <tel:313-876-1850>
23. <mailto:Kcampan1@hfhs.org>
24. <tel:319-356-1826>
25. <mailto:mclean-sunderland@uiowa.edu>
26. <mailto:jodie.mactagone@providence.org>
27. <tel:513-658-5866>
28. <mailto:lcharris@wakehealth.edu>

29. <mailto:francisco.martinez@northwestern.edu>
30. tel:801-507-9333
31. <mailto:johnny.trang@imail.org>
32. tel:718-904-2321
33. <mailto:ofelia.garcia@einsteinmed.edu>
34. tel:781-744-3874
35. tel:+41613241111
36. <mailto:>
37. tel:1-888-669-6682
38. <mailto:novartis.email@novartis.com>